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Cancers occurring at the gastroesophageal junction (GEJ) are classiﬁed as predominantly esophageal or gastric, which is often
difﬁcult to decipher. We hypothesized that the transcriptomic proﬁle might reveal molecular subgroups which could help to
deﬁne the tumor origin and behavior beyond anatomical location. The gene expression proﬁles of 107 treatment-naïve,
intestinal type, gastroesophageal adenocarcinomas were assessed by the Illumina-HTv4.0 beadchip. Differential gene
expression (limma), unsupervised subgroup assignment (mclust) and pathway analysis (gage) were undertaken in R statistical
computing and results were related to demographic and clinical parameters. Unsupervised assignment of the gene expression
proﬁles revealed three distinct molecular subgroups, which were not associated with anatomical location, tumor stage or grade
(p > 0.05). Group 1 was enriched for pathways involved in cell turnover, Group 2 was enriched for metabolic processes and
Group 3 for immune-response pathways. Patients in group 1 showed the worst overall survival (p = 0.019). Key genes for the
three subtypes were conﬁrmed by immunohistochemistry. The newly deﬁned intrinsic subtypes were analyzed in four
independent datasets of gastric and esophageal adenocarcinomas with transcriptomic data available (RNAseq data: OCCAMS
cohort, n = 158; gene expression arrays: Belfast, n = 63; Singapore, n = 191; Asian Cancer Research Group, n = 300). The
subgroups were represented in the independent cohorts and pooled analysis conﬁrmed the prognostic effect of the new
subtypes. In conclusion, adenocarcinomas at the GEJ comprise three distinct molecular phenotypes which do not reﬂect
anatomical location but rather inform our understanding of the key pathways expressed.
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Introduction
Incidence of tumors at the gastroesophageal junction (GEJ) has
increased rapidly over the past 50 years.1 Current clinical classi-
ﬁcation systems for these tumors are primarily based on the
location of the main tumor mass and do not consider tumor
biology.2 These systems have been developed to facilitate the
decision making for the optimal surgical approach, which was
historically the mainstay of treatment. With newly emerging
systemic treatment options and multimodal therapy concepts
being more dominant in curative treatment approaches, under-
standing of the biological processes that deﬁne different tumor
subtypes is becoming increasingly important.
According to current knowledge, cancers in the distal part of
the GEJ (Siewert Type 3) are more likely to arise from the prox-
imal stomach.3–7 Proximal GEJ tumors (Siewert Type 1), on the
other hand, are most likely of esophageal origin.5 It remains not
clear if tumors originating directly from the GEJ (Siewert
Type 2) comprise a mixed group of esophageal or gastric can-
cers or if these constitute a separate entity with distinct biologi-
cal behavior. A recent study from The Cancer Genome Atlas
(TCGA) consortium compared the genomic, epigenetic and
transcript proﬁles of esophageal and gastric cancers comprising
approximately 550 cancers.8 Interestingly, the authors concluded
that esophageal, junctional and gastric adenocarcinomas are
generally of a similar nature, with the majority of junctional
cancers belonging to the chromosomal instability (CIN) subtype
that has been described in their previous cohort of gastric can-
cers.9 CIN tumors were mainly intestinal-type cancers according
to the Laurén classiﬁcation, as is expected for junctional can-
cers.3 Previous studies comparing junctional cancers to “true
gastric” adenocarcinomas have often included diffuse-type gas-
tric tumors in the analyses introducing a bias due to the differ-
ent cancer biology and a distinct genomic proﬁle compared to
intestinal type cancers.9 Previous molecular classiﬁcations were
mainly based on the genomic features which do not necessarily
reﬂect the active gene transcription landscape.
The primary aim of our study was to deﬁne adenocarci-
nomas at the GEJ according to their transcriptomic proﬁle.
Cases were very carefully selected to ensure that we had precise
information on the location of the tumor in relation to the GEJ
coupled with other clinical annotation. Since the Siewert classi-
ﬁcation is the current gold standard for clinical stratiﬁcation
of these tumors, we ensured that we had this information on
each case in order to compare it with the molecular subtypes
obtained.10 We also performed a pathway analysis of key
expressed genes from each subgroup to further deﬁne the bio-
logical features of these subgroups and performed immunohis-
tochemistry for selected genes to check expression at the
protein level. The ﬁndings were conﬁrmed in transcriptomic
data from four independent datasets with clinical outcome data.
Materials and Methods
Study cohorts
All tissue samples were chemotherapy and radiotherapy-naïve
and prospectively collected either (i) as part of the Oesophageal
Cancer Clinical and Molecular Stratiﬁcation (OCCAMS) study
consortium, coordinated by the University of Cambridge,
United Kingdom, (ii) at the local tissue bank at Addenbrooke’s
Hospital, Cambridge University Hospitals (local ethics refer-
ence 10/H0305/1), or (iii) at the University of Magdeburg,
Germany, Department of Gastroenterology, Hepatology &
Infectious Diseases (local ethics references 132/01 and 34/08),
before being retrospectively assessed for inclusion in our study.
All patients gave written informed consent to tissue archiving
and further analyses. The study was conducted in accordance
with the Declaration of Helsinki. Tissue samples were
obtained either during diagnostic endoscopy or surgical re-
section of the tumor. Diffuse-type cancers and tumors with
mixed pathology were excluded for the reasons explained in
the Introduction.
A total of 84 patients with intestinal type adenocarcinoma at
the GEJ as deﬁned by Siewert and Stein in 1998 (35 GEJ1: main
tumor mass 1–5 cm proximal to the junction, 31 GEJ2: 1 cm
proximal to 2 cm distal to the junction, 18 GEJ3: 2–5 cm distal
to the junction10) were included in two batches. For compari-
son, 23 nonjunctional gastric cancers (8 antrum, 15 gastric
body) were included, as well as 11 mucosal biopsies from four
noncancer controls (4 duodenum, 3 gastric body, 4 gastric car-
dia; local ethics reference LREC 01/149). Samples with histolog-
ical evidence of squamous contamination as indicated by clear
enrichment of genes associated with squamous differentiation
were removed (n = 23) from the core analysis, leaving n = 61
GEJ cancers. Refer to Supporting Information Figure S1 for fur-
ther details on the cohort selection process.
Four independent cohorts were used for validation purposes.
The OCCAMS RNASeq cohort comprised 158 esophageal and
GEJ adenocarcinomas. The “BELFAST” cohort included trans-
criptomic data from an additional 63 esophageal adenocarcinomas
What’s new?
Adenocarcinomas that arise at the junction between the esophagus and the stomach are currently classiﬁed based on location.
Here, the authors looked at patterns of gene expression of these cancers. They found that gastro-esophageal junction
adenocarcinomas can be sorted into three biological subtypes, independent of location, based on gene expression. Group
1 cancers have boosted stomach-speciﬁc genes that combat the effects of acid reﬂux. Group 2 tumors express genes
characteristic to the intestinal tract, and the genes active in Group 3 relate to inﬂammation. The differences in biological
pathway expression means that these differences could be used to improve treatment.
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based on a modiﬁed Affymetrix expression array. The “SINGA-
PORE” cohort comprised 191,11 the “ACRG” (Asian Cancer
Research Group) cohort of 300 true gastric cancers of Asian
origin for comparison12 (see further details below).
RNA and DNA extraction
Snap-frozen tissue samples and matched blood, as a germline
reference, were utilized. One section of the sample was stained
with hematoxylin and eosin (H&E) and sent for cellularity
review (≥70% tumor cellularity required for cancer samples)
by at least two expert pathologists. Careful macrodissection and
microdissection were performed to maintain this cellularity
threshold.
RNA/DNA extraction was performed using the AllPrep kit
(Qiagen, Hilden, Germany) and using the QIAamp DNA
Blood Maxi kit (Qiagen, Hilden, Germany). RNA with an
RNA integrity number (RIN) >7.0 was used for cDNA prepa-
ration (applying for material extracted from both biopsies and
surgical resection specimens). Gene expression analysis was
carried out on Illumina HT12 version 4.0 beadchip kit.
Whole-genome sequencing analysis
For 41 GEJ cases, whole-genome sequencing (WGS) data was
generated with 50× coverage for the cancer samples and 30×
for germline reference samples as part of the International
Cancer Genome Consortium (ICGC). Somatic mutations and
indels were called using Strelka 1.0.13.13 Copy numbers were
called using ASCAT-NGS v2.114 with the read counts at
germline heterozygous positions as input for ASCAT being
obtained using GATK 3.2-2. Mutational signatures were iden-
tiﬁed using the methodology described by Alexandrov et al.15
To assess the alterations in DNA damage-related pathways in
our cohort, we performed an analysis similar to the one
described by Pearl et al.16 Refer to the Supporting Information
Methods for further details on the genomic analysis.
RNA sequencing
For the OCCAMS validation cohort of 158 samples, trans-
criptome data was generated by RNA sequencing. Libraries were
prepared using the Illumina TruSeq Stranded Total RNA Library
Prep Kit and 75 bp paired-end sequencing was performed using
the HiSeq 4000 System. RNA-seq data were aligned to the
GRCh37_g1k reference genome using TopHat2. Aligned primary
reads were then counted and normalized for gene length and
sequencing depth. Log transformation of the expression data was
performed as additional step of normalization before ﬁnal analy-
sis. Downstream analysis (see below) highlighted four outlier
samples with extreme distribution of the gene expression pattern
which were removed from further analysis resulting in 154 sam-
ples that were used for further validation.
Immunohistochemistry
For a subset of 30 treatment-naïve cancers for which surgical
resection specimens were available (GEJ1: n = 4, GEJ2: n = 6,
GEJ3: n = 6, body: n = 8, antrum: n = 6) immunohistochemi-
cal staining was performed on the Leica Bond-II autostainer.
For all markers, a semiquantitative analysis of the cyto-
plasmatic staining was performed according to the modiﬁed
immunoreactivity score by Remmele and Stegner multiplying
the intensity of the cytoplasmatic staining (0: absent–3: strong
signal) with the proportion of stained tumor cells (0: none–10:
100%).17
Transcriptomic data analysis
All transcriptome data analyses were performed on R statisti-
cal computing using Bioconductor18 packages. All differential
gene expression analyses were performed using limma in R.19
p Values for limma-based differential gene expression analyses
were adjusted for multiple comparison and represent false dis-
covery rates (FDRs) for the respective tests. All unbiased
group assignment was performed using mclust in R.20 Refer to
Supporting Information Methods for further details.
The primary data sets for our study can be accessed as
GSE96669. Publicly available datasets were used for validation:
“BELFAST” dataset (E-MTAB-4666), the “SINGAPORE”
cohort (GSE1545911) and the data of the Asian Cancer Research
Group (“ACRG”; GSE6622912). Further datasets included were
from colorectal (GSE38832), breast (GSE58812) and lung cancer
samples (GSE31210).
Results
Comparison of the transcript proﬁle of GEJ adenocarcinoma
Sixty-one junctional adenocarcinomas across all three Siewert
types (GEJ1: 26, GEJ2: 22, GEJ3: 13) were included in the core
analysis. There was no signiﬁcant difference in clinical param-
eters between the Siewert types, apart from an expected higher
proportion of Barrett’s esophagus in patients with GEJ1 can-
cers. Patients underwent standard clinical treatment pathways
according to their stage (Fig. 1a) and there was no signiﬁcant
difference in median survival between GEJ1 (22.2 m), GEJ2
(25.9 m) and GEJ3 (29.9 m) tumors (p = 0.251; Fig. 1b).
Differential gene expression analysis between tumors of
different Siewert types using limma19 revealed that REC8
(REC8 Meiotic Recombination Protein) was the only gene
with differential expression when comparing between GEJ1
and GEJ3 tumors (FDR: p = 0.004), and SESN1 (Sestrin-1)
between GEJ2 and GEJ3 tumors (FDR: p = 0.024). There were
no differentially expressed genes below the threshold of
p = 0.01 when GEJ1 tumors were compared to GEJ2 cancers
(Figs. 1c and 1d; Supporting Information Table S1). Further-
more, there were no differentially expressed genes between
junctional and nonjunctional cancers (Supporting Information
Table S1). When the ﬁrst two principal components of the
transcript proﬁle of these 84 gastroesophageal cancers were
displayed, a random distribution was observed according to
the anatomical location (Fig. 2a).
Next, we applied an unbiased approach to identify molecu-
larly intrinsic cancer subtypes. Using the mclust algorithm,20
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an optimal solution of three distinct subgroups for the core
cohort of 61 GEJ cancers emerged (Supporting Information
Fig. 2a). Patients were thus assigned by mclust to three sub-
groups and a group-by-group differential gene expression
analysis was performed to identify genes deﬁning each sub-
type (Supporting Information Table S2). Of these, 82 genes
with a p-score <0.0001 (Supporting Information Methods)
were considered as candidates for discrimination between the
new subtypes. Since location had no impact on the analysis of
differentially expressed genes between tumors of different
Siewert types and junctional vs. nonjunctional cancers, we also
performed a combined analysis with the 23 nonjunctional gas-
tric tumors which resulted in a similar three group distribu-
tion (Fig. 2a, Supporting Information Fig. S2b). Of the genes
mentioned above, 67 genes (82%) were also represented in
this parallel analysis which were then selected for further vali-
dation (Fig. 2b, Supporting Information Methods).
Since GEJ cancers can express a range of intestinal cell
types, we also compared the gene expression proﬁle of the iden-
tiﬁed subtypes with samples from gastric and duodenal mucosa
of patients without cancer. Compared to these noncancer
mucosal controls, upregulation of cancer-speciﬁc genes was
conﬁrmed but no further genes were highlighted (Supporting
Information Table S3).
Thirty patients for which high-quality surgical resection
specimens were available were selected for immunohistochem-
istry to investigate if the new subtypes could also be con-
ﬁrmed at the protein level. Markers were selected according to
the ﬁrst and second principal component of the gene expres-
sion data analysis (Fig. 3).
The immunostaining scores for all markers were as expected
for each subgroup (Supporting Information Table S4). For
CTSE (p = 0.047) and membranous CLDN18 (p = 0.048), the
absolute scores were signiﬁcantly different between the three
Figure 1. Comparison of clinical and gene expression data for GEJ cancers of different Siewert type. Panel (a) shows the distribution of UICC
stage (p = 0.347), grading of the tumor (p = 0.823), presence of Barrett’s esophagus (p < 0.001) and proportion of patients on a curative
treatment pathway (p = 0.139) for GEJ Type 1, Type 2 and Type 3 cancers, respectively. There was no statistically signiﬁcant difference in
censored overall survival between cancers of different Siewert type as shown in (b). The boxplots in (c) show the relative expression of genes
REC8 and SESN1, which were the only differentially expressed genes in pairwise differential gene expression comparison of GEJ cancers.
Panel (d) shows the respective volcano plots for the differential gene expression analyses.
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subgroups with the highest scores for Group 1. SULF1
(a marker for stromal activation) was more intensely stained
in patients of Group 1 and Group 2 (p = 0.004). Presence of
IDO1 positive immune cells was highest in Group 3 tumors
(90%; p = 0.217) and was associated with IP10 expression in
the tumor (p = 0.017).
Pathway analysis support different biological background of
the three subtypes
In order to better understand the biological pathways underpin-
ning the new group assignment, gene-set enrichment analysis was
performed using gage in R.21 Based on KEGG terms, the top
essential pathways enriched in Group 1 were “Ribosome,” “Fatty
Acid Metabolism,” “Oxidative Phosphorylation” and pathways
involved in nucleic acid turnover (both DNA and RNA). Group
2 was characterized by “Steroid Hormone Biosynthesis,”
“Peroxisome,” “Primary Bile Acid Biosynthesis” and terms related
to metabolic processes. Essential KEGG pathways enriched in
Group 3 were “Antigen Processing and Presentation,” “Chemo-
kine Signaling Pathways” and “Natural Killer Cell-Mediated
Cytotoxicity,” among other immune-response related terms
(Table 1; Supporting Information Table S4). These results
were in line with a parallel analysis based on gene ontology
terms (Supporting Information Table S5).
A complementary Ingenuity® Pathway Analysis (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity) showed
broadly similar results (Supporting Information Table S6). The
expression proﬁle of Group 1 was associated with canonical
pathways involved in the degradation of organic substances,
with the top regulatory networks being related to fatty acid
metabolism. Group 2 showed enrichment for genes involved in
retinoic acid receptor activation, bile acid biosynthesis and endo-
thelin signaling. Group 3 was characterized by canonical path-
ways involved in immune response and cell–cell interaction.
Association of the three subtypes to clinical and genomic
parameters
Next, we assessed whether there was any association between the
new subtypes and clinical parameters. Of 107 cancers, 28 (26.2%)
were assigned to Group 1, 39 (36.4%) to Group 2 and 40 (37.4%)
Figure 2. Gene expression proﬁle of different subgroups of junctional and nonjunctional intestinal-type adenocarcinomas. Panel (a) shows
the principal component plots for the distribution of the samples according to the ﬁrst two principal components of the gene expression
analysis. The top panel shows the distribution according to location of the main tumor mass, the bottom panel the subgroups as identiﬁed
by mclust (the color code is displayed in the bottom middle). The heatmap in panel (b) illustrates the clustering of the new subtypes (group
1: green, group 2: red, group 3: blue). Displayed are the combined group of 61 GEJ and 23 nonjunctional cancers (columns) and the target
set of 67 genes (rows, see main text for details).
Bornschein et al. 5
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
to Group 3. Overall, there was no relevant difference between the
groups with regards to clinical or demographic factors (Fig. 4a;
Supporting Information Table S7). When only patients with
cancer at the GEJ were analyzed, there was a strong association
of the presence of Barrett’s esophagus with the new subgroups
(Group 1: 93.3%, Group 2: 60.7%, Group 3: 40.9%; p = 0.004).
Figure 3. Immunohistochemistry proﬁle of the three subtypes of gastroesophageal adenocarcinoma. The immunohistochemical staining for
markers that were ranked highest in the principal component analysis is shown for the respective groups. One representative case for each
group is displayed. For some of the markers, distinction was more obvious (e.g., CTSE more strongly expressed in Group 1, and CDH17 more
strongly expressed in the Group 2), whereas for some markers differences were subtler (e.g., nuclear staining of CDX1 in Group 2 or
cytoplasmic staining of IP10 in Group 3). For MUC5AC cytoplasmic staining and extracellular mucin is assessed, for CTSE, and IP10
cytoplasmic staining is typical, for CLDN18 and CDH17 membranous staining, and for CDX1 nuclear staining.
6 Molecular proﬁling of adenocarcinoma at the gastroesophageal junction
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Kaplan–Meier analysis revealed a difference in the median
overall survival between the three subtypes, with borderline
statistical signiﬁcance (Group 1: 25.9 m vs. Group 2: 45.2 m
vs. Group 3: 83.5 m; p = 0.019; Fig. 4b) compared to the
other known clinical parameters: stage of disease (p < 0.001),
T-stage (p < 0.001), nodal involvement (p < 0.001) and pres-
ence of distant metastases (p < 0.001).
Cox regression analysis showed that the new tumor subtype
was an independent prognostic factor for overall survival with a
Hazard ratio of 1.506 (95% conﬁdence interval: 1.021–2.222;
p = 0.039), along with nodal involvement and distant metasta-
ses. There was no difference in the proportion of patients who
underwent a curative or a palliative treatment pathway between
each group (Fig. 4c, Supporting Information Table S7).
For 41 cases, WGS data were available to compare the
genomic properties of the new subtypes. Bearing in mind the
heterogeneous nature of genomic alterations in this cancer
and the relatively small sample size with WGS available,22
Figure 4. Comparison of clinicopathological data and overall survival for the new subgroups based on the whole study cohort (n = 107).
Panel (a) shows the distribution of UICC stage (p = 0.058), T-stage (p = 0.178), nodal involvement (p = 0.865), presence of distant
metastases (p = 0.234), as well as grading of the tumor (p = 0.451) for the new subgroups. Censored overall survival for each subgroup is
shown in the Kaplan–Meier graph in (b) with group one showing the worst and Group 3 the best prognostic outcome. The proportion of
patients on a curative treatment pathway for each group (p = 0.531) is displayed in (c).
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there was no demonstrable difference between the three sub-
types with regards to the overall mutational burden and the
proﬁle of copy number aberrations and ampliﬁcations or dele-
tions (Supporting Information Fig. 3a). There was enrichment
across all groups for mutational signatures 1, 2, 3 and 17 as
deﬁned by Alexandrov et al.15 (Supporting Information Fig. 3b),
which was as expected for gastroesophageal adenocarcinomas.22
Group 3 showed a slightly higher prevalence for alterations in
genes involved in DNA damage repair (DDR) pathways (check-
point factors, chromatin remodeling, Fanconi anemia, telomere
maintenance, translesion synthesis; Supporting Information
Fig. 3c). In keeping with this, this subgroup also showed a higher
proportion of “DDR impaired” positive tumors according to the
classiﬁcation recently published by our group22 although it
did not reach statistical signiﬁcance due to the relatively small
numbers with WGS data available (Supporting Information
Figs. 4a and 4b).
Application of new subtype classiﬁcation in independent
cohorts
It is crucial to determine if these ﬁndings are reproducible in
other datasets across other platforms. Four further datasets
were available for analysis. These were not necessarily focused
on junctional tumors but demonstrate the broad applicability
of these molecular subgroups to esophageal and gastric adeno-
carcinomas independent of their anatomical location. While
the OCCAMS dataset was generated based on RNA-sequenc-
ing, the BELFAST, SINGAPORE and ACRG datasets were
generated on Affymetrix platforms. The 67 genes panel was
applied to all four validation cohorts (Supporting Information
Methods) for subtype assignment.
The 154 samples of the OCCAMS cohort recapitulated a
three-group solution as expected (Group 1: n = 51, Group 2:
n = 77, Group 3: n = 26), which was also the case for the
63 esophageal adenocarcinomas of the BELFAST cohort
(Group 1: n = 26, Group 2: n = 15, Group 3: n = 22). The
191 gastric adenocarcinomas from the SINGAPORE cohort11
(tumors of unclear histological subtype were excluded),
could also be classiﬁed into the three groups (Group 1:
n = 78, Group 2: n = 66, Group 3: n = 47); and subtype assign-
ment was also consistent for the 300 gastric cancers of the
Asian Cancer Research Group (ACRG)12 (Group 1: n = 85,
Group 2: n = 108, Group 3: n = 107; Fig. 5a). For the latter two
Asian validation cohorts, our classiﬁcation showed statistical
overlap (p < 0.001) with the subtypes that have been previously
proposed by Lei et al.11 and Cristescu et al.,12 but the distri-
bution of the subtypes within the cohorts suggested a distinct
classiﬁcation (Fig. 5b). Ethnic origin did not inﬂuence the
results since there was no difference in the subtype distribu-
tion between Western (OCCAMS, BELFAST and primary
study cohort) and Asian (SINGAPORE, ACRG) patients
(p = 0.967). This was also the case when cohorts with pre-
dominantly esophageal cancers were compared to gastric
tumor cohorts (p = 0.351).
A pooled analysis of all 815 cases across all ﬁve cohorts
(including our primary study cohort) showed signiﬁcantly
different median overall survival, with Group 1 showing the
worst and Group 3 the best prognosis (p = 0.001). Similarly to
our primary cohort, also grade of differentiation (p < 0.001),
UICC stage (p < 0.001), nodal involvement (p < 0.001) and
distant metastases were inﬂuencing factors (p < 0.001). Cox
regression analysis including stage, grading and the new sub-
types as factors conﬁrmed both stage of disease (p < 0.001)
and the new subtypes (p = 0.002) as independent prognostic
factor, whereas grading was not conﬁrmed (p = 0.169). In the
individual validation cohorts, a moderate statistical difference
in outcome could be seen in the BELFAST (p = 0.038) and
the SINGAPORE (p = 0.007) cohort, but not in the ACRG
(p = 0.075) and OCCAMS (p = 0.796) datasets (Fig. 5d).
To check whether the ﬁndings were cancer type speciﬁc we
applied our gene panel to datasets from other tumor entities
(colorectal, lung and breast) which interestingly also clustered
into three groups suggesting that there may be some modules
common across multiple cancer types, but they did not show
differences in survival (Supporting Information Fig. 5).
Discussion
These data conﬁrm that the biological properties of adenocar-
cinomas at the GEJ are independent of the anatomical loca-
tion of the main tumor mass. Adenocarcinomas at the GEJ
and nonjunctional gastric cancers of the intestinal type can be
stratiﬁed into three biologically distinct subtypes based on
their gene expression proﬁle.
The pathway analysis gives some insight into the biological
basis for each tumor subtype. Group 1 shows features which
appear to be in keeping with mucosal damage by reﬂux compo-
nents including enrichment of stomach-speciﬁc genes, particu-
larly CLDN18 which is upregulated under reﬂux conditions to
increase mucosal resistance to acid23 and MUC5AC which is
upregulated in response to bile exposure.24 In addition, the meta-
bolic processes enhanced in this group indicate a possible inter-
action with visceral adipocytes. Adipose tissue can constitute a
proinﬂammatory microenvironment in obese patients, leading to
stromal activation which is associated with more aggressive
tumor behavior and poor prognosis.25–29 Negative regulators of
adipogenesis like BMP and activin membrane-bound inhibitor
(BAMBI) or transglutaminase 2 (TGM2) showed the lowest
expression in Group 1 (Supporting Information Fig. S6).30,31
Group 2 is characterized by metabolic pathways which are
usually active in the intestinal and hepatobiliary tract. Expres-
sion of the intestinal transcription factor CDX2 can also be
induced by exposure to bile acids, mediated by the farnesoid
X receptor.32 The intestinal properties of Group 2 are further
supported by expression of Achaete-scute family bHLH tran-
scription factor 2 (ASCL2), an intestinal stemness marker
(Supporting Information Fig. S6).
Group 3 is linked to inﬂammatory response regulation
showing a threefold to ﬁvefold higher expression of CD8A
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(T-cell marker CD8) and GZMB (granzyme B, marker of
cytotoxic activity) compared to the other groups (Supporting
Information Fig. S6). Gastric cancers with a high ratio of
tumor-inﬁltrating lymphocytes show a better prognosis and are
associated with impairment in mismatch repair pathways.33
DDR impairment can also be associated with chronic infection
with H. pylori,34 and is a feature of a subtype of esophageal
adenocarcinomas with a higher mutational and neo-antigen
burden.22 While the small subcohort for which WGS data were
analyzed showed a trend toward a higher proportion of “DDR
impaired” tumors22 in Group 3, this association was not con-
ﬁrmed in the OCCAMS validation cohort. In this cohort,
Group 2 tumors showed a higher proportion of the “DDR
impaired” genome signature type. It is of note that there is
some overlap between the dominant genes for Group 2 and
Group 3 (Fig. 2). It requires further elucidation in larger
cohorts to determine whether our transcriptome-based classiﬁ-
cation is linked to genome-based subtypes.
We also assessed the association of our new subgroups to
MSI status using data from the OCCAMS cohort for which
WGS data was available. MSI status was classiﬁed as MSI stable
(MSS) or MSI-low/high (MSI-L/H) as described before.22 While
91.4% of patients were classiﬁed as MSS, 8.6% were MSI-L/H
and there was no association of MSI status to the new sub-
groups (p = 0.361). The low prevalence of MSI positive cases is
in keeping with previous reports for this disease.9 However, we
also compared MLH1 status that was provided for the ACRG
cohort with the new subtype classiﬁcation. Of 300 cases 23.1%
were MLH1-negative indicating MSI-H status. This was more
often seen in Group 3 (32.9%) when compared to groups 1
(18.7%) and Group 2 (14.8%; p = 0.007). Although there is
some overlap, MSI status affects only about a third of patients
in Group 3 and is therefore unlikely to be a dominant discrimi-
nating factor for our classiﬁcation.
Interestingly, there is a strong association between the new
subgroups and presence of Barrett’s esophagus. If only patients
with junctional cancers were analyzed, there was a dominance
of Barrett’s positive cases for the subgroups with stromal
enhancement and worse prognosis. These data need to be inter-
preted with care due to the limited numbers in our study and
the incomplete data regarding prevalence of Barrett’s esopha-
gus. The signiﬁcantly higher prevalence of Barrett’s esophagus
Figure 5. Comparison of subtype distribution and survival in independent cohorts. Panel (a) shows the distribution of each subtype in our
primary cohort and across the four validation cohorts (please see main text for further details). We also compared the group stratiﬁcation as
originally published for the SINGAPORE and ACRG cohorts (b). On the left we show the distribution of the originally published subtypes within
our new groups for each cohort, on the right the distribution of our newly deﬁned subtypes within each subtype that has previously been
published by Lei et al. and (top) Cristescu et al. (bottom). Despite a signiﬁcant statistical overlap between the different group stratiﬁcations,
there are still considerable differences in the distribution. The Kaplan–Meier curve in (c) shows the cumulative overall survival (in months)
for each of the new subtypes in the pooled cohort of all 815 patients across all ﬁve subcohorts (Group 1: green, Group 2: red, Group 3: blue).
The Kaplan–Meier curves below (d) show the outcome for each of the validation cohorts.
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is in line with the results of the pathway analysis being sugges-
tive of an inﬂuence of bile exposure as well as visceral adipo-
cytes (as seen in obesity) playing a relevant role, both risk
factors also relevant for Barrett’s metaplasia and its progression.
Our study was not designed to develop a prognostic pre-
dictor panel. Explorative analysis of the available clinical
data showed a modest prognostic effect that we interpret
rather as proof-of-principle data supporting the biological
relevance of our subtypes, rather than being of robust prog-
nostic value when compared to other studies.35,36 It is encour-
aging that our classiﬁcation is also supported by the results
from further independent datasets given that these comprised
RNA-Seq data or were generated on Affymetrix-based plat-
forms, whereas we used Illumina. Two of these cohorts com-
prised mainly cancers from Asian populations resulting in a
different genetic background and different exposure to risk
factors when compared to the Western patients of our pri-
mary cohort.11,12 Although there seems to be some overlap
between our new subgroups and the previously published
classiﬁcations, study objectives, methods and design differed
from our approach.
Interestingly, Kim and colleagues published data on a
cohort of 64 patients with EAC, also demonstrating three
subgroups when applying nonsupervised clustering on array-
based transcriptome data.37 They also demonstrated an associ-
ation of their subgroup with prognosis. The gene list that
served as the foundation for the subgroup assignment is not
disclosed so comparison to our groups is limited. Further-
more, the target genes used for subgroup validation were
selected based on Cox regression analysis and prognostic rele-
vance whereas we aimed at selection based on biological dom-
inance in the principal component analysis. It requires further
prospective validation if our markers or the ones described by
others before are useful for clinical application, and if so in
which setting (e.g., as a prognostic marker, for treatment
assignment or for individual preneoplastic risk assignment).
We acknowledge that the results regarding different prognos-
tic outcome for each group were not consistent across all indi-
vidual validation datasets, but, most importantly, the three
molecular subtypes were conﬁrmed for all four validation
cohorts, independent from the ethnic origin of the respective
cohorts and the platform used for expression analysis.
The staining results in our cohort further support the trans-
criptome analysis. Some of the immunohistochemical markers
have also been previously tested in malignant and premalignant
stages of colorectal and gastroesophageal cancers.38,39 The com-
bination of CDH17 and CLDN18, for example, has been con-
ﬁrmed as being predictive for nodal involvement and poor
prognosis in gastric adenocarcinomas.40 CLDN18 is a dominant
marker in our poor prognosis Group 1 and CDH17 is charac-
teristic for Group 2 which shows intermediate outcome in our
primary cohort, but poor prognosis in some of the validation
cohort. Some of our target genes have also been reported to be
relevant for subtypes of pancreatic and right-sided colorectal
cancer, suggesting that similar mechanisms such as exposure to
small bowel content (including bile and pancreatic enzymes)
might be involved in carcinogenesis of gastroenteropancreatic
tumors.38,41 Similarly, dysregulation of speciﬁc transcription
factors in Barrett’s esophagus have been reported to be compa-
rable to gene signals seen in normal colonic mucosa.42 Of note
is the high expression of SULF1 in the two groups with poorer
prognosis indicating again the relevance of stromal activation
as poor prognostic factor. Saadi et al. demonstrated previously
that there is a stage-dependent stromal signature in Barrett’s
metaplasia, dysplasia and EAC that is associated with progno-
sis.43 While the aim of the previous study was the selection of a
gene panel with optimal prognostic properties in the present
study we aimed to an understanding of the biological back-
ground of the newly identiﬁed subtypes. This paves the way for
further work to determine clinical signiﬁcance.
In summary, our data show that the transcriptomic proﬁles
of GEJ tumors reﬂect distinct molecular subgroups of intesti-
nal type gastro-esophageal adenocarcinomas indicative of cell
biological function which is independent of anatomical loca-
tion. Further understanding the biology of these subtypes will
help to reﬁne efforts for individualized targeted treatment as
well as strategies for early detection and prevention.
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